| Q36354948 | A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. |
| Q91785476 | AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation? |
| Q89777956 | Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 |
| Q92954779 | Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies |
| Q92563311 | Assessment of haematopoietic progenitor cell counting with the Sysmex® XN-1000 to guide timing of apheresis of peripheral blood stem cells |
| Q64118048 | Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia |
| Q57135413 | Attitude of A Sample of Iranian Researchers toward The Future of Stem Cell Research |
| Q92836012 | Autologous Bone Marrow Stem Cell Transplantation in Liver Cirrhosis after Correcting Nutritional Anomalies, A Controlled Clinical Study |
| Q38838220 | Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas |
| Q38880448 | Automatic washing of thawed haematopoietic progenitor cell grafts: a preclinical evaluation |
| Q49835956 | Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study |
| Q94562861 | Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia |
| Q89674644 | Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults |
| Q94954577 | Building a hematopoietic cell transplantation outcomes registry in Mexico |
| Q49344260 | Burden of oral mucositis in stem cell transplant patients-the patients' perspective. |
| Q57171765 | Cancer immunotherapy with CAR-T cells - behold the future |
| Q50050452 | Cardiovascular risk factors and subclinical organ damage after hematopoietic stem cell transplantation in pediatric age. |
| Q94948686 | Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT |
| Q41558781 | Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia |
| Q90182584 | Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT |
| Q41600980 | Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts |
| Q47734612 | Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. |
| Q47114304 | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. |
| Q92735544 | Considerations for haploidentical versus unrelated donor transplants |
| Q40527491 | Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation |
| Q88498533 | Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality |
| Q47922371 | Cryopreservation of adult unrelated donor products in hematopoietic cell transplantation: the OneMatch experience and systematic review of the literature |
| Q91341172 | Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial |
| Q47447522 | Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG). |
| Q93252156 | Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma |
| Q49904514 | Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most |
| Q48138880 | Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents |
| Q50025694 | Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the rand |
| Q45875683 | Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients |
| Q37718993 | Expression of Serum microRNAs is Altered During Acute Graft-versus-Host Disease |
| Q57166265 | Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape |
| Q89482977 | Fertility preservation in an adolescent boy: inducing puberty and spermatogenesis prior to elective, non-urgent bone marrow transplantation |
| Q90355897 | First Ready, First to Go: Ethical Priority-Setting of Allogeneic Stem Cell Transplant at a Major Cancer Centre |
| Q39013204 | G-CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield. |
| Q52659308 | Genomic Integration of HHV-6 Mimicking Viral Reactivation after Autologous Stem Cell Transplantation. |
| Q33770125 | Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia |
| Q92735530 | Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT |
| Q94570196 | Hematopoietic Stem Cell Transplantation in Egypt: Challenges and Opportunities |
| Q87709285 | Hematopoietic cell transplantation in MDS: undervalued and underutilized |
| Q92437786 | Hematopoietic cell transplants in Jordan: different indications from the US and EU |
| Q58545119 | Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute |
| Q33601663 | Hepatitis E and blood donation safety in selected European countries: a shift to screening? |
| Q36287792 | High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. |
| Q88609462 | High-dose chemotherapy and autotransplants for plasma cell myeloma in Jordan |
| Q37134694 | Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor |
| Q92877680 | Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation |
| Q39209783 | Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). |
| Q90050645 | Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation |
| Q64088774 | Incidence, Risk Factors and Prognosis of Acute Kidney Injury Following Hematopoietic Stem Cell Transplant: A Pilot Study |
| Q91016714 | Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. |
| Q57818274 | Infection Complications in Hematopoietic Stem Cells Transplant Recipients: Do Genetics Really Matter? |
| Q50959656 | Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. |
| Q33774610 | Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target |
| Q91556007 | Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study |
| Q92498075 | Invasive Fungal Infection |
| Q58751499 | Is a matched unrelated donor search needed for all allogeneic transplant candidates? |
| Q59938773 | Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report |
| Q38739178 | JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. |
| Q88483072 | JACIE accreditation from the perspective of an accredited centre |
| Q90267017 | LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society f |
| Q89262674 | Lost in Transplantation? Unexpected shift from multipotent to late lymphomyeloid hematopoietic stem and progenitor cells in patients 1 year after hematopoietic stem cell transplantation |
| Q90132008 | Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEO |
| Q48297094 | More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Work |
| Q30245682 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report |
| Q28075654 | Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia |
| Q28069889 | Novel therapeutic options in Acute Myeloid Leukemia |
| Q64074893 | Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation |
| Q93062722 | Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis |
| Q52763577 | Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. |
| Q92399602 | Pleiotropic roles of autophagy in stem cell-based therapies |
| Q38880504 | Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. |
| Q48251589 | Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score |
| Q47561039 | Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. |
| Q91945674 | Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation |
| Q92039526 | Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy |
| Q64240236 | Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study |
| Q89673632 | Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia |
| Q38937601 | Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation |
| Q91682914 | Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab |
| Q89777916 | Related haploidentical donors are a better choice than matched unrelated donors: Point |
| Q58088033 | Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors |
| Q40175242 | Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies |
| Q36244335 | Revisiting nutritional support for allogeneic hematologic stem cell transplantation-a systematic review. |
| Q48192483 | Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors. |
| Q94550540 | Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease |
| Q41995676 | Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation. |
| Q88562103 | Standardising busulfan dosage for children and young adults |
| Q91487226 | Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for B |
| Q89623577 | Survival analysis of multiple myeloma patients after autologous stem cell transplantation |
| Q60915997 | Targeting JNK pathway promotes human hematopoietic stem cell expansion |
| Q89748159 | The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus |
| Q91387141 | The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies |
| Q91711253 | The Graft-Versus-Leukemia Effect in AML |
| Q38728327 | The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy |
| Q89776845 | The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis |
| Q91452397 | The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma |
| Q33786536 | Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. |
| Q89223921 | Young child as a donor of cells for transplantation and lymphocyte based therapies |
| Q87986419 | [Advances in haploidentical hematopoietic stem cell transplantation for myelodysplastic syndromes] |